Article
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Nature metabolism - 1 Dec 2020
Kim Jiyeon, Lee Hyun Min, Cai Feng, Ko Bookyung, Yang Chendong, Lieu Elizabeth L, Muhammad Nefertiti, Rhyne Shawn, Li Kailong, Haloul Mohamed, Gu Wen, Faubert Brandon, Kaushik Akash K, Cai Ling, Kasiri Sahba, Marriam Ummay, Nham Kien, Girard Luc, Wang Hui, Sun Xiankai, Kim James, Minna John D, Unsal-Kacmaz Keziban, DeBerardinis Ralph J
Abstract excerpt
In non-small-cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and the tumour suppressor STK11 (also known as LKB1) encoding the kinase LKB1 result in aggressive tumours prone to metastasis but with liabilities arising from reprogrammed metabolism. We previously demonstrated perturbed nitrogen metabolism and addiction to an unconventional pathway of pyrimidine synthesis in KRAS/LKB1 co-mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.